These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 14744791)
1. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Ge Y; Jensen TL; Stout ML; Flatley RM; Grohar PJ; Ravindranath Y; Matherly LH; Taub JW Cancer Res; 2004 Jan; 64(2):728-35. PubMed ID: 14744791 [TBL] [Abstract][Full Text] [Related]
2. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366 [TBL] [Abstract][Full Text] [Related]
3. Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. Ge Y; Jensen TL; Matherly LH; Taub JW Blood; 2003 Feb; 101(4):1551-7. PubMed ID: 12393509 [TBL] [Abstract][Full Text] [Related]
4. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Taub JW; Huang X; Matherly LH; Stout ML; Buck SA; Massey GV; Becton DL; Chang MN; Weinstein HJ; Ravindranath Y Blood; 1999 Aug; 94(4):1393-400. PubMed ID: 10438727 [TBL] [Abstract][Full Text] [Related]
5. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Taub JW; Matherly LH; Stout ML; Buck SA; Gurney JG; Ravindranath Y Blood; 1996 Apr; 87(8):3395-403. PubMed ID: 8605357 [TBL] [Abstract][Full Text] [Related]
6. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome. Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808 [TBL] [Abstract][Full Text] [Related]
10. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Abraham A; Varatharajan S; Abbas S; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P Pharmacogenomics; 2012 Feb; 13(3):269-82. PubMed ID: 22304580 [TBL] [Abstract][Full Text] [Related]
11. Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells. Kanno S; Hiura T; Ohtake T; Koiwai K; Suzuki H; Ujibe M; Ishikawa M Clin Chim Acta; 2007 Feb; 377(1-2):144-9. PubMed ID: 17097625 [TBL] [Abstract][Full Text] [Related]
12. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Gandhi V; Estey E; Keating MJ; Chucrallah A; Plunkett W Blood; 1996 Jan; 87(1):256-64. PubMed ID: 8547650 [TBL] [Abstract][Full Text] [Related]
13. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy. Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660 [TBL] [Abstract][Full Text] [Related]
14. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia. Caldwell JT; Edwards H; Dombkowski AA; Buck SA; Matherly LH; Ge Y; Taub JW PLoS One; 2013; 8(7):e68601. PubMed ID: 23874683 [TBL] [Abstract][Full Text] [Related]
16. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells. Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565 [TBL] [Abstract][Full Text] [Related]
17. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131 [TBL] [Abstract][Full Text] [Related]
18. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine]. Xie XT; Jiang SY; Li BS; Yang LL Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730 [TBL] [Abstract][Full Text] [Related]
19. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells. Grant S; Bhalla K; McCrady C Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601 [TBL] [Abstract][Full Text] [Related]
20. Natural history of GATA1 mutations in Down syndrome. Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]